Date: 2013-04-18
Type of information: Production agreement
Compound: investigational cell therapy product TK
Company: MolMed (Italy) Zambon (Italy)
Therapeutic area: Cancer - Oncology
Type agreement: manufacturing
production
Action mechanism:
Disease:
Details: MolMed has announced the signature of an agreement for the future lease of real estate in the \"Open Zone\" scientific park located in Bresso (Milan, Italy) owned by Zambon, aimed at the expansion of the production capacity of the Company. This expansion is necessary both to support the treatment of patients with TK therapy in the ongoing Phase III trial and for the future commercialization of the product, and to intensify development and production activities of novel gene and cell therapy treatments for third parties.
Financial terms:
Latest news:
